^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MAGE-A3 modulator

    Related drugs:
    6ms
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Oct 2026 --> Mar 2029
    Trial completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    9ms
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    almost2years
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    over2years
    KITE-718-301: Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=16, Terminated, Kite, A Gilead Company | Active, not recruiting --> Terminated; The study was terminated due to the sponsor's decision to discontinue the clinical trial.
    Trial termination • Metastases
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    cyclophosphamide • fludarabine IV • KITE-718
    over2years
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Dec 2023
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    almost3years
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2022 --> Jun 2023
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    over3years
    Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Kite, A Gilead Company | Trial completion date: Mar 2022 --> Oct 2022
    Trial completion date
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    cyclophosphamide • fludarabine IV • KITE-718
    over3years
    Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov)
    P2, N=80, Completed, Gliknik Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    MAGEA3 (MAGE Family Member A3)
    |
    cyclophosphamide • Hiltonol (poly-ICLC) • Leukine (sargramostim) • biropepimut-S (GL-0817)
    almost4years
    Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. (PubMed, Cochrane Database Syst Rev)
    The immunological interventions were active immunotherapy Bacillus Calmette-Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural killer (NK) cells...Two trials provided health-related quality of life results with contradicting results.  AUTHORS' Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC.
    Review • Journal • Checkpoint inhibition
    |
    MAGEA3 (MAGE Family Member A3)
    |
    Stimuvax (tecemotide)
    almost4years
    Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer. (PubMed, Front Oncol)
    Through further analysis, the positive rate of MAGEA3 was related to the stage and transfer number of lymph nodes. These results indicated that MAGEA3 is a novel biomarker and correlated with lymph node metastasis and immune infiltrates in GC, which could be a new target for immunotherapy.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    MAGEA3 (MAGE Family Member A3)
    4years
    A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=86, Recruiting, Cancer Research UK | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    4years
    Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. (PubMed, BMC Cancer)
    The IFN-γ ELISPOT assay characterized distinct profiles of tumour-antigen-specific T cell responses in HCC patients. CTA- and SALL4-specific T cell responses may be important for controlling HCC in the early stage, whereas AFP-specific T cell responses might be a signature of malignant tumour status in the advanced stage. The application of immunotherapy at an early stage of HCC development should be considered.
    Journal
    |
    IFNG (Interferon, gamma) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • SALL4 (Spalt Like Transcription Factor 4)